Thursday, September 8, 2011

Study: Under-Eye Fat Transfer Lasts a Few Years

Dr. Z wants to share this article from:

NEW YORK (Reuters Health) - Fat transferred under the eyes to create a younger-looking face can last for at least three years, suggests a new study of people who had the surgery. 

The procedure involves liposuction from the abdominal area or thighs and then injection of the fat below the lower eyelid, to puff up an area that surgeons say generally begins to lose its shape by the time people are in their 30s. 

Doctors say it's more "natural" and lasts longer than injecting commercially-made wrinkle fillers, but there's also a risk of complications and a higher price tag that comes along with the fat-transfer surgery.

"It's becoming a very common procedure and a way to naturally rejuvenate especially the lower eyelid area," said study author Dr. Cory Yeh, a plastic surgeon from Laguna Woods, California. 

"The vast majority of patients are seeing results up to three years," Dr. Yeh told Reuters Health. "The question is always, are we going to be seeing results past that point?"

Surgeons said the procedure typically takes an hour or more, and costs $3,500 to $4,000. 

For the new study, published in Archives of Facial Plastic Surgery, online July 18, Dr. Yeh and Dr. Edwin Williams, from the Albany Medical Center in New York, tracked photos of 99 people who had the fat-transfer surgery between 2004 and 2008. 

Patients were between 35 and 71 years old, and almost all were women.

Those patients came back to the office for photos of their eye area every few months for up to four years following the surgery. Without knowing when the photos were taken, other members of the study team rated how much improvement, if any, they saw in patients' faces from their original, pre-surgery photos.
In pictures taken a year or less after the surgery, 5% of patients showed no improvement, 51% had mild improvement, and 44% had marked improvement.

By two to three years post-surgery, 14% of patients had no improvement from their original photos, 68% had mild improvement and 18% had marked improvement -- but the researchers only had data on 22 patients that far out. 

The most common complication of the surgery was swelling lasting more than a couple of weeks. Some patients also had bruising under the eyes or minor asymmetries. Patients can also get small lumps under their eyes post-surgery, researchers said.

Dr. Yeh said the findings "matched our expectations" in terms of how long the results would hold up after surgery.

"We know that the person's going to continue to age, and that they're going to continue to lose volume" under the eyes, he said. "I would have been shocked if we'd said, 'No, everybody remains perfect.'"
Dr. Jason Meier, a plastic surgeon from Jacksonville, Florida, said the procedure is a few times more expensive than typical commercial injections, but that those injections need to be repeated about every year. 

The current study didn't look at any results from patients who got those injections. 

"Fat transfer is an excellent, permanent option for patients who want a natural, rejuvenated look in the under-eye area," Dr. Meier, who wasn't involved in the new research, told Reuters Health. 

"Some things don't end up perfectly precise," but that can be corrected with follow-up procedures, he added. "Uniformly, everyone is very satisfied."

Dr. Yeh said the extra volume may not last as long in elderly patients, or those that smoke or exercise a lot.
But he said the fat-transfer procedure is becoming more common, and that it's "appealing to many patients because this is a natural way of using their own body fat."

By Genevra Pittman

Wednesday, September 7, 2011

Stem Cells - Revolutionizing Cosmetic Surgery!


Dr. Z wants to share this article from PRNewswire, Vienna!
 
 
Experts Meet at ICAS Conference in Istanbul

Esthetic therapies with stem cells from autologous fat are revolutionizing cosmetic surgery: Ever more women prefer breast augmentations with autologous stem cells over silicone implants. The world's leading experts recently met at the ICAS (International Cell Assisted Surgery) Conference in Istanbul to discuss the therapeutic potential of stem cells from fat tissue.

"Stem cell-enriched autologous fat is a safe and sustainable bioimplant ideally suited for local anesthesia natural, scarless breast augmentation and body shaping," says Viennese esthetic and regenerative stem cell therapy expert DDr. Karl-Georg Heinrich, Europe's first doctor offering this therapy. At Clinic DDr. Heinrich® he helps women from all around the world gain larger breasts, harmonious body contours, and a more youthful face with stem cell-enriched autologous fat.

Along with presentations by researchers on the latest findings on adipose-derived stem cells (ADSC) and their esthetic applications, the conference provided experts with ample opportunities for professional interaction. Thus DDr. Heinrich discussed his experiences with adipose-derived stem cells and potential future applications with Japan's Prof. Dr. Yoshimura, Prof. Dr. Illouz, and Dr. Berman.

Doctors all agreed that stem cell enrichment substantially improves long-term sustainability of tissue implanted in autologous fat transfers. Also discussed was the greater safety of esthetic therapies with autologous stem cells over procedures under general anesthesia thanks to gentle local anesthesia.

In addition to stem cell-assisted breast augmentation, stem cells obtained from autologous fat deposits form the foundation for other future-oriented esthetic treatments. For instance, Dr. Heinrich also uses stem cell-enriched autologous fat for sustainable body shaping (e.g., buttocks augmentation), correcting tissue defects, skin rejuvenation over the whole body, and stem-cell facelifts.

Tuesday, September 6, 2011

NFL Player Injuries Linked to Low Vitamin D

Dr. Z wants to share this article from:
 
 
Berkeley Heights, N.J. — Vitamin D deficiency may be unusually high among American football players, with black players and those with muscle injuries showing significantly lower levels, Medscape Today reports. 


Berkeley Heights orthopedic surgeon Michael K. Shindle, M.D., led a research team that tested the vitamin D levels of 89 players from the National Football League’s New York Giants in the spring of 2010. 

Investigators found that 27 players — about 30 percent — had deficient total 25-hydroxy vitamin D levels (below 20 ng/mL) and as many as 45 players — just over half — had levels consistent with vitamin D insufficiency (between 20 and 31.9 ng/mL). 


Meanwhile, only 17 players — about 19 percent — had vitamin D levels that were within normal limits.
The percentage of players with abnormal vitamin D levels was “alarming,” according to Dr. Shindle.
Researchers also found that all players who had suffered injuries that caused them to miss at least one practice or game had vitamin D levels significantly lower than players with no muscle injury. 


Of the players tested, 31 were white and 58 black. Noting that blacks generally tend to have lower vitamin D levels than whites, Medscape Today quotes Dr. Shindle as saying, “Up to 93 percent of African-American players had abnormal vitamin D levels, compared with 31 percent of white players.” 


The study was presented at the annual meeting of the American Orthopaedic Society for Sports Medicine, held recently in San Diego.

This article can also be viewed at: http://bit.ly/nfWCvt


Dermatology Times E-News

Friday, September 2, 2011

FDA OKs Study of ReCell for Scars

Dr. Z wants to share this article from:


Northridge, Calif. — The Food and Drug Administration has approved Avita Medical’s investigational device exemption feasibility study for the use of ReCell Spray-On-Skin in the treatment of hypertrophic dyspigmented scars.

The FDA protocol permits Avita to treat 20 patients with pre-existing scars at as many as four U.S. study sites. The treated scars will be assessed for healing and pain on a weekly basis during the initial four weeks post-treatment, and at weeks 12 and 24 the treatment site will be assessed for healing and aesthetic outcomes by both the patient and the surgeon.

In a company news release, Avita CEO William Dolphin, M.D., said, “We believe that ReCell offers the potential to deliver significant benefits over currently available options in the treatment of acute and chronic wounds and skin defects. This study will allow us to demonstrate the use of ReCell in the corrective treatment of existing scars with application to the very large cosmetic markets.”

The study is designed to assess the effectiveness of using ReCell for the treatment of existing scars in a single treatment session, compared to the current standard of care, which involves dermabrasion and often requires multiple sessions.

Data obtained from this feasibility study will be used to design a larger clinical investigation. Once the 12-week follow-up with the 20th patient is completed, Avita will submit the feasibility data to the FDA and will seek approval for the pivotal trial protocol.

Avita Medical is currently conducting an FDA-approved study for the use of ReCell in the treatment of acute burn wounds.

By Bill Gillette, Staff Correspondent

Friday, August 26, 2011

Pressure Device Treats Ear Keloids

 Dr. Z wants to share this article from:



Mannheim, Germany — Results of a small study suggest that there is significant potential for a pressure device used to supplement other treatments for auricular keloids, Medical News Today reports. 

Between December 2007 and March 2009, a research team headed by Gregor M. Bran, M.D., of the University Hospital of Mannheim, investigated the auricular pressure device in seven patients being treated for auricular keloids. Patients underwent surgical removal of the keloids and injection of corticosteroids, after which they were told to wear the pressure device overnight for a minimum of five nights a week until either the scar level matched the level of surrounding healthy skin, or after two consecutive adjustments in the device produced no improvement. Custom-designed for each patient, the two-piece device was held in position by magnets along the ear’s rim. 

No problems were reported during the prescribed time in which patients wore the device, and no patients interrupted or stopped the treatment. After an average follow-up of 24 months, no recurrence of keloids was seen in any patient. All patients reported satisfaction with the results and no patient reported itch, pain or abnormal sensations. 

Researchers wrote that while the use of pressure devices in the treatment of keloids of the ear is not new, the device they tested more adequately meets the requirements of an ideal auricular pressure device. They concluded that larger, center-based trials with long-term follow-up will allow better understanding of the role the device could play in improving scar management. 

The study was reported in Archives of Facial Plastic Surgery.


Dermatology Times E-News

Tuesday, August 23, 2011

Chimp Attack Victim Reveals New Face

Dr. Z is sharing this article from:




Boston — The woman who received a full face transplant after being attacked by a chimpanzee in 2009 has publicly revealed her new face while recovering at Brigham and Children’s Hospital, Boston, Medical News Today reports.

Charla Nash, 57, received the face transplant in May. The procedure, led by Bohdan Pomahac, M.D., included a team of 30 doctors, nurses and anesthesiologists. The transplant provided Ms. Nash with facial skin, a nose and lips, according to the report. Ms. Nash lost her upper jaw, nose, lips and most of the soft tissue on her face in the chimp attack, CNN.com reports. She was also left blind and lost her hands.
Surgeons had also performed a double hand transplant, but circulation problems forced doctors to later remove them. Ms. Nash may eventually be a candidate to receive another hand transplant, Medical News Today reports.

The full face transplant involved removing some tissue and attaching skin to underlying muscle in an effort to provide motor and sensory functions. The surgical team also transplanted the entire hard palate and teeth. Surgeons expect that the full face transplant will eventually allow Ms. Nash to express herself facially.




Cosmetic Surgery Times E-News

Read Full Article at http://bit.ly/pesucb

Monday, August 22, 2011

Biomarkers Can Predict Sensitizers

Dr. Z is bringing this article to you from:




Lund, Sweden — Laboratory-grown human cells can now be used to classify chemicals as sensitizing or nonsensitizing and can predict the strength of allergic response, thus providing an alternative to animal testing, ScienceDaily reports.

Researchers from Lund University in Sweden used genome-wide profiling to measure the response of a human myeloid leukemia cell line to known chemicals. From this they defined a biomarker signature of 200 genes that could accurately discriminate between sensitizing and nonsensitizing chemicals. By comparing this signature with the known action of these chemicals, they also were able to predict sensitizing potency.


European legislation restricts animal testing within the pharmaceutical and cosmetic industries. The new research provides a potential alternative testing method to ensure that new drugs are hypoallergenic, investigators note.


Cosmetic Surgery Times E-News

Read full article at http://bit.ly/pls8U7